CN101461937A - Pig interferon inducer and use - Google Patents
Pig interferon inducer and use Download PDFInfo
- Publication number
- CN101461937A CN101461937A CNA200810164106XA CN200810164106A CN101461937A CN 101461937 A CN101461937 A CN 101461937A CN A200810164106X A CNA200810164106X A CN A200810164106XA CN 200810164106 A CN200810164106 A CN 200810164106A CN 101461937 A CN101461937 A CN 101461937A
- Authority
- CN
- China
- Prior art keywords
- pig
- interferon
- polysaccharide
- interferon inducer
- inducer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides a pig interferon inducer. The active components of the pig interferon inducer consist of purified pig alpha-interferon, ginseng polysaccharide, ginsenoside, hydroxymethyl tuckahoe polysaccharide and polysaccharide-peptide. By weighing up the active components and adding with glycerin and gelatin for fully mixing, a suspending liquid is prepared, and the suspending liquid needs to be stored in light-shading places. For porcine reproductive respiratory syndrome, hog cholera and pseudorabies, the effective prevention rate of the pig interferon inducer provided by the invention is more than 70 percent. The invention provides a veterinary medicine which is safe, effective and low-priced, and can prevent diseases, and the cells are induced to generate the interferon by stimulating an animal body, so that the veterinary medicine has various biological activities of resisting virus in the broad spectrum, improving body immunity and the like, and the aims of preventing and curing viral diseases are achieved. The pig interferon inducer has the advantages of solving the problems of high production cost and inconvenient use existing in the leukocyte interferon and the recombination interferon of the pig, along with simple production process, low production cost and convenient popularization.
Description
Technical field
The invention belongs to field of veterinary, relate to a kind of pig interferon inducer, relate in particular to a kind of through inducing veterinary drug that produces antiviral antibody, antiviral protein and endogenous interferon and uses thereof.
Background technology
Interferon (IFN) is a kind of broad-spectrum disease resistance toxic agent, direct killing or inhibition are not viral, and mainly be after being subjected to virus or the stimulation of other interferon induceres by cell surface, a kind of effect with high activity, multi-functional glycoprotein that is produced by body cells such as situation cell, lymphocytes makes cell produce antiviral protein, thereby suppresses duplicating of virus; Also can strengthen natural killer cell (NK cell), macrophage and the lymphocytic vigor of T simultaneously, thereby play immunoregulation effect, and strengthen anti-virus ability, substitute the antibiotic use of part.Pig interferon can be used for immune swine fever, PRV (Pseudorabies virus), pig blue-ear disease poison etc., but because in the market interferon goods exist costs an arm and a leg, shortcomings such as complex manufacturing, thus obstructed the use of interferon.
Summary of the invention
The object of the invention is to provide a kind of pig interferon inducer, and its active component is made up of purification porcine alpha-interferon, ginseng polysaccharide, ginsenoside, methylol pachyman and polysaccharide-peptide, and each constituent mass percentage composition is:
Purification porcine alpha-interferon 28.8
The ginseng polysaccharide 5
The ginsenoside 5
Methylol pachyman 1
Polysaccharide-peptide 0.2
Glycerol 20
Gelatin 20
Another purpose of the present invention provides the preparation method of pig interferon inducer, realize by following steps: accurately purification porcine alpha-interferon 28.8%, ginseng polysaccharide 5%, ginsenoside 5%, methylol pachyman 1%, polysaccharide-peptide 0.2% are got in weighing, add 20% glycerol and 20% gelatin fully mixes, make suspension, divide and install in the sterilization bottle ware, quality inspection is put in storage then, and finished product is preserved at dry, lucifuge place.
A further object of the present invention provides the application of pig interferon inducer in preparing treatment and prevention pig blue-ear disease poison, swine fever, pseudorabies medicine.
The dosage form of compositions of the present invention is outstanding agent, and route of administration is an oral administration, and the 0.01ml/Kg dosed administration is pressed in sub-service once a day, serve on 7 days.
A kind of pig interferon inducer provided by the invention, to pig blue-ear disease poison, swine fever, the effective prevention rate of porcine pseudorabies more than 70%.Select for use glycerol and gelatin substrate pair and interferon to have protective effect in the preparation, make interferon activity stable.The present invention is to provide a kind of safe and effective, cheap prophylactic veterinary drug, produce interferon by stimulation animal body inducing cell, thereby have multiple biological activity activity such as broad-spectrum antiviral and enhancing human body immunity power, reached the purpose of preventing and treating viral disease.The invention solves shortcomings such as leukocyte interferon of pig and recombinant interferon production cost height, use inconvenience.Production technology is simple, and cost of manufacture is cheap, is fit to promote the use of
The specific embodiment
The present invention is further described in conjunction with specific embodiments.
Embodiment 1
Accurately purification porcine alpha-interferon 28.8%, ginseng polysaccharide 5%, ginsenoside 5%, methylol pachyman 1%, polysaccharide-peptide 0.2% are got in weighing, add 20% glycerol and 20% gelatin fully mixes, make suspension, divide and install in the sterilization bottle ware, quality inspection is put in storage then, and finished product is preserved at dry, lucifuge place.
The using method of this inducer: oral according to the ratio of 0.1ml/Kg, used continuously 7-10 days.Preparation technology's flow process:
The test of embodiment 2 animal safeties
Laboratory animal: 240 of 21 age in days ablactational baby pig.
Experimental technique: be divided into three groups at random, 80 every group.First group as blank group, not administration; Second group according to 0.01ml/Kg dosage, by oral the said goods, ablactational baby pig is carried out feeding continuously in 7 days, and the 3rd group is added Western medicine is the glad soluble powder western medicine group of rich network, administration 7 days, and one week of drug withdrawal is observed growth and the incidence of ablactational baby pig.
Experimental result is referring to table 1.
Table 1
| Group | The morbidity number | The survival number | Death toll | Sickness rate | Mortality rate |
| 1 | 13 | 76 | 4 | 16.25％ | 5.00％ |
| 2 | 4 | 80 | 0 | 5.00％ | 0 |
| 3 | 9 | 77 | 3 | 11.25％ | 3.75％ |
Experiment finishes to observe to be found, first group is that the blank group is tested when finishing, and the piglet sickness rate is 16.25%, and wherein piglet pujos blancos accounts for 3.75%, piglet red dysentery accounts for 3.75%, yellow scour of piglet accounts for 1.25%, and swine fever accounts for 2.50%, 1.25% and the pseudorabies symptom occurs: short of breath, in disorder by hair, do not eat or the appetite minimizing, have sharp ears is blue, and 3.75% is unknown morbidity.Mortality rate is 5.00%, and wherein 1.25% is piglet pujos blancos, and 1.25% is piglet red dysentery, and 1.25% is swine fever, and porcine pseudorabies accounts for 1.25%.
When second group of experimental group was oraferon inducer group experiment end, the piglet sickness rate was 5.00%, and wherein piglet pujos blancos accounts for 1.25%, and it is unknown morbidity that piglet red dysentery accounts for 1.25%, 2.50%.Mortality rate is 0%.The 3rd group is that western medicine group is tested when finishing, and the piglet sickness rate is 11.25%, and wherein piglet pujos blancos accounts for 2.50%, piglet red dysentery accounts for 1.25%, and yellow scour of piglet accounts for 1.25%, and swine fever accounts for 2.50%, 1.25% the pseudorabies symptom occurs: short of breath, in disorder by hair, not eat or the appetite minimizing, have sharp ears is blue, 1.25% the symptom of reproductive and respiratory syndrome occurs: alveolar septum thickens, monocyte infiltration and II type epithelial hyperplasia have the non-viable non-apoptotic cell fragment in the alveolar space, 1.25% is unknown morbidity.Mortality rate is 3.75%, and wherein 1.25% is piglet pujos blancos, and 0% is piglet red dysentery, and 0% is yellow scour of piglet, and 1.25% is swine fever, and porcine pseudorabies accounts for 1.25%.
Embodiment 3
Laboratory animal: be selected from 240 of 80Kg growing and fattening pigs
Experimental technique: be divided into three groups at random, 80 every group.First group as blank group, not administration; Second group according to 0.01ml/Kg dosage, and oral the said goods carries out feeding continuously in 7 days to ablactational baby pig, and the 3rd group is added Western medicine is the glad soluble powder western medicine group of rich network, administration 7 days, and one week of drug withdrawal is observed growth and the incidence of ablactational baby pig.
Experimental result is referring to table 2.
Table 2
| Group | The morbidity number | The survival number | Death toll | Sickness rate | Mortality rate |
| 1 | 18 | 77 | 3 | 22.50％ | 3.75％ |
| 2 | 2 | 80 | 0 | 2.50％ | 0 |
| 3 | 9 | 78 | 2 | 11.25％ | 2.50％ |
Experiment finishes to observe to be found, first group is that the blank group is tested when finishing, and the pig sickness rate is 22.50%, wherein swine fever accounts for 7.50%, 6.25% and the pseudorabies symptom occurs: short of breath is in disorder by hair, do not eat or the appetite minimizing, have sharp ears is blue, and 8.75% is unknown morbidity.Mortality rate is 3.75%, and wherein 2.50% is swine fever, and 1.25% is porcine pseudorabies.
Second group of experimental group is oraferon inducer group experiment when finishing, and the pig sickness rate is 2.50%, and wherein to account for 0%, 2.50% be unknown morbidity to swine fever.Mortality rate is 0%.
The 3rd group is that western medicine group is tested when finishing, and the pig sickness rate is 11.25%, and swine fever accounts for 5.00%, 3.75% the pseudorabies symptom occurs: short of breath, and in disorder by hair, do not eat or the appetite minimizing, have sharp ears is blue, 2.50% the symptom of reproductive and respiratory syndrome occurs: alveolar septum thickens, and monocyte infiltration and II type epithelial hyperplasia have the non-viable non-apoptotic cell fragment in the alveolar space, mortality rate is 3.75%, wherein 2.50% is swine fever, and 1.25% is porcine pseudorabies, and 0% is unknown disease.
Claims (6)
1. pig interferon inducer, it is characterized in that: its active component is made up of purification porcine alpha-interferon, ginseng polysaccharide, ginsenoside, methylol pachyman and polysaccharide-peptide, and each constituent mass percentage composition is:
Purification porcine alpha-interferon 28.8
The ginseng polysaccharide 5
The ginsenoside 5
Methylol pachyman 1
Polysaccharide-peptide 0.2
Glycerol 20
Gelatin 20.
2. the preparation method of pig interferon inducer according to claim 1, it is characterized in that realizing by following steps: accurately purification porcine alpha-interferon 28.8%, ginseng polysaccharide 5%, ginsenoside 5%, methylol pachyman 1%, polysaccharide-peptide 0.2% are got in weighing, add 20% glycerol and 20% gelatin fully mixes, make suspension, divide and install in the sterilization bottle ware, quality inspection is put in storage then, and finished product is preserved at dry, lucifuge place.
3. the application of pig interferon inducer according to claim 1 in preparation prevention and treatment pig blue-ear disease cytotoxic drug.
4. the application of pig interferon inducer according to claim 1 in the medicine of preparation prevention and treatment swine fever.
5. the application of pig interferon inducer according to claim 1 in the medicine of preparation prevention and treatment porcine pseudorabies.
6. according to the application of the arbitrary described pig interferon inducer of claim 3-5, it is characterized in that: the dosage form of described medicine is outstanding agent, and route of administration is an oral administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810164106XA CN101461937A (en) | 2008-12-25 | 2008-12-25 | Pig interferon inducer and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810164106XA CN101461937A (en) | 2008-12-25 | 2008-12-25 | Pig interferon inducer and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101461937A true CN101461937A (en) | 2009-06-24 |
Family
ID=40802873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200810164106XA Pending CN101461937A (en) | 2008-12-25 | 2008-12-25 | Pig interferon inducer and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101461937A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103446207A (en) * | 2013-01-11 | 2013-12-18 | 上海禾易生物技术发展有限公司 | Preparation method and application of reagent for activating human immune cells |
| CN107950775A (en) * | 2017-12-29 | 2018-04-24 | 湖北浩华生物技术有限公司 | A kind of pig interferon derivant and its preparation method and application |
-
2008
- 2008-12-25 CN CNA200810164106XA patent/CN101461937A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103446207A (en) * | 2013-01-11 | 2013-12-18 | 上海禾易生物技术发展有限公司 | Preparation method and application of reagent for activating human immune cells |
| CN107950775A (en) * | 2017-12-29 | 2018-04-24 | 湖北浩华生物技术有限公司 | A kind of pig interferon derivant and its preparation method and application |
| CN107950775B (en) * | 2017-12-29 | 2021-04-27 | 湖北浩华生物技术有限公司 | Porcine interferon inducer and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bricknell et al. | The use of immunostimulants in fish larval aquaculture | |
| CN103535529B (en) | Traditional Chinese medicine feed additive, preparation method of additive, and feed containing additive | |
| CN103169773B (en) | Traditional Chinese medicine compound preparation for enhancing livestock immunity and preparation method | |
| CN101057971A (en) | Medicine for controlling livestock-poultry virus infectious disease | |
| CN103110024A (en) | Antiviral feed Chinese herbal medicine additive for broiler chicken and production method thereof | |
| CN102119765A (en) | Immunopotentiator for large yellow croaker adults | |
| CN102100784A (en) | Animal immunoenhancement taking Echinacea as main component | |
| Mesalhy et al. | Echinacea as immunostimulatory agent in Nile tilapia (Oreochromis niloticus) via earthen pond experiment | |
| CN101461937A (en) | Pig interferon inducer and use | |
| CN101721685A (en) | Animal interferon liquid spray and preparation method thereof | |
| Vail et al. | Adjunct treatment of equine respiratory disease complex (ERDC) with the propionibacterium acnes, immunostimulant, EqStim® | |
| CN104208677A (en) | Mixed freeze-dried powder for preventing chicken Newcastle disease, infectious bronchitis, egg drop syndrome, and bird flu, and preparation method thereof | |
| CN102078598B (en) | Injection for preventing and treating porcine viral diseases and preparation method thereof | |
| CN102698244B (en) | Drug composition used for preventing piglets from diarrhea and promoting piglets to grow | |
| CN103751253B (en) | A kind of veterinary medical composition for the treatment of swine fever and its production and use | |
| CN107998332B (en) | Traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome and application thereof | |
| CN109528853A (en) | A kind of Chinese medicine composition and preparation method thereof for treating female pig blue-ear disease | |
| CN105749278A (en) | Porcine pseudorabies-preventing composition, preparation method and application | |
| CN105724826A (en) | Prawn feed additive and application thereof | |
| CN104208681B (en) | A kind of freeze-dried mixed powder of anti-duck viral disease and preparation method thereof | |
| CN109481591A (en) | The Chinese medicine composition and preparation method thereof for treating curing gallinaceous leucocyto zoonosis | |
| CN104256065A (en) | Traditional Chinese medicine composition for feeding eriocheir sinensis and use method | |
| CN103844001A (en) | Compound premix for pig | |
| CN103908479A (en) | Medical hydrogel for treating gynecological diseases or skin diseases and application of medical hydrogel | |
| CN103341160B (en) | A kind of pharmaceutical composition and application thereof containing interferon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090624 |